NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Stock Has Consensus Target Price of $48.90

Shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) have been assigned a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $48.70.

Several equities analysts have recently commented on the company. Wall Street Zen raised NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a research report on Sunday, November 1st. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, October 15th. Needham & Company LLC reduced their price target on NewAmsterdam Pharma from $48.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and issued a $52.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, September 8th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $45.00 price objective on shares of NewAmsterdam Pharma in a research report on Monday, July 20th.

Insider Activity at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, CEO Michael Davidson purchased 10,000 shares of the stock in a transaction that occurred on Monday, September 14th. The shares were acquired at an average cost of $22.65 per share, with a total value of $226,500.00. Following the completion of the transaction, the chief executive officer owned 792,923 shares in the company, valued at $17,959,705.95. The trade was a 1.28% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John W. Smither sold 1,600 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $25.32, for a total value of $40,512.00. Following the sale, the director directly owned 8,760 shares in the company, valued at $221,803.20. This represents a 15.44% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 176,846 shares of company stock worth $4,661,919. Corporate insiders own 12.74% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of large investors have recently bought and sold shares of NAMS. Frazier Life Sciences Management L.P. boosted its position in NewAmsterdam Pharma by 6.8% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock worth $613,033,000 after purchasing an additional 1,145,128 shares during the period. Bank of America Corp DE increased its holdings in NewAmsterdam Pharma by 84.4% in the 1st quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock valued at $27,115,000 after purchasing an additional 387,698 shares in the last quarter. Maverick Capital Ltd. raised its position in NewAmsterdam Pharma by 15.4% in the first quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock valued at $69,987,000 after purchasing an additional 292,176 shares during the period. SEB Asset Management AB purchased a new position in NewAmsterdam Pharma in the first quarter valued at about $8,728,000. Finally, Stempoint Capital LP lifted its stake in shares of NewAmsterdam Pharma by 147.1% during the first quarter. Stempoint Capital LP now owns 180,658 shares of the company’s stock worth $5,783,000 after purchasing an additional 107,552 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

NewAmsterdam Pharma Trading Up 0.1%

NAMS stock opened at $18.90 on Friday. The firm has a market capitalization of $2.26 billion, a PE ratio of -11.18 and a beta of 0.15. NewAmsterdam Pharma has a 1-year low of $18.50 and a 1-year high of $42.21. The business’s 50 day simple moving average is $22.10 and its 200 day simple moving average is $29.52.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.33. The business had revenue of $19.16 million during the quarter, compared to the consensus estimate of $8.82 million. NewAmsterdam Pharma had a negative return on equity of 31.39% and a negative net margin of 789.95%. As a group, sell-side analysts predict that NewAmsterdam Pharma will post -1.62 EPS for the current fiscal year.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.